Practice Areas

ANZ's New Zealand unit says it may be on the hook for $102.5 million (NZ$125 million) after losing a class action alleging it failed to repay fees and interest wrongly charged to customers who took out home or personal loans.

Two Sydney University academics facing discrimination suits over alleged antisemitic statements have argued proposed amendments risk blowing up the cases into "another royal commission".

A global settlement may now be within reach in a class action brought by Navy technicians over training contracts after a larger number of same group members' claims have been assessed, a court has heard. 

Mastercard's Australia boss was anxious to sign a deal with Woolworths on payments processing after learning that Coles had chosen to route all debit transactions through the cheaper EFTPOS network, a court has heard.

The Full Court has tossed a former Neometals employee's appeal of his failed whistleblower case, finding the company did not believe he had made a protected disclosure when making him redundant despite the company conceding that the was "somebody who frequently raised issues".

A joint venture contracted to build a battery storage facility in the Melbourne Renewable Energy Hub, expected to be one of the world's largest, has dropped a suit against renewables developer Equis alleging it was entitled to a 50 per cent reduction in its bank guarantees.

Hassall Developments wants to join insurance broker Gallagher to a lawsuit against QBE over an $80 million special risks policy after “serious defects” were allegedly found in a Parramatta development. 

Adani has asked the court to toss a class action by First Nations landowners over media statements made during a dispute over the Carmichael open cut mine in Queensland.

Private toll road operator Atlas Arteria has urged shareholders to reject a $7 billion hostile takeover offer from IFM Investors that allegedly undervalues the company.

Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.